#1 Clinical Trials Search in Europe

Methoxsalen

Methoxsalen, also known as 8-methoxypsoralen, is a drug being studied in clinical trials for its potential therapeutic effects in various medical conditions. This article explores the use of methoxsalen, often in combination with ultraviolet light therapy called extracorporeal photopheresis (ECP), across different diseases including skin disorders, graft-versus-host disease, autoimmune conditions, and more. We’ll examine ongoing research to understand how this treatment approach may benefit patients.

Table of Contents

What is Methoxsalen?

Methoxsalen, also known by its brand name UVADEX[1], is a medication used in conjunction with a treatment called extracorporeal photopheresis (ECP). This drug belongs to a class of compounds called psoralens, which are light-sensitive substances. Methoxsalen is typically used as a sterile solution that interacts with ultraviolet A (UVA) light during the ECP procedure[2].

How Methoxsalen Works

Methoxsalen works by making certain cells in your body more sensitive to UVA light. During the ECP procedure, some of your blood is temporarily removed from your body. The white blood cells are separated and mixed with methoxsalen. These cells are then exposed to UVA light, which activates the methoxsalen. When these treated cells are returned to your body, they help regulate your immune system[3].

This process can have various effects on your immune system, including:

  • Reducing inflammation
  • Modifying the behavior of certain immune cells
  • Potentially helping your body fight certain diseases

Conditions Treated with Methoxsalen

Methoxsalen, when used with ECP, has been studied and used to treat several conditions:

  1. Cutaneous T-Cell Lymphoma (CTCL): This is a type of skin cancer affecting certain white blood cells called T-cells. Methoxsalen with ECP is approved for treating the skin symptoms of CTCL, particularly in its early stages[4].
  2. Graft-versus-Host Disease (GvHD): This is a complication that can occur after bone marrow or stem cell transplants. Methoxsalen with ECP has shown promise in both preventing and treating GvHD[1][5].
  3. Crohn’s Disease: This is a type of inflammatory bowel disease. Research has been conducted to explore the use of methoxsalen with ECP in treating moderate Crohn’s disease that hasn’t responded well to other treatments[6].
  4. Rheumatoid Arthritis: This is an autoimmune disease that causes joint inflammation. Studies have investigated the potential of methoxsalen with ECP in treating rheumatoid arthritis that hasn’t responded adequately to other treatments[7].
  5. Immune-related Colitis: This is an inflammation of the colon that can occur as a side effect of certain cancer treatments. Research is ongoing to evaluate the effectiveness of methoxsalen with ECP in treating this condition[8].

How Methoxsalen is Administered

Methoxsalen is not taken like a typical medication. Instead, it’s used as part of the ECP procedure, which is performed in a medical setting. Here’s a general overview of how it’s administered:

  1. You may be given methoxsalen orally about 1-2 hours before the ECP procedure[3].
  2. During the ECP procedure, some of your blood is collected through a vein.
  3. The white blood cells are separated from your blood.
  4. These cells are mixed with methoxsalen and exposed to UVA light.
  5. The treated cells are then returned to your body[2].

The frequency of treatments can vary depending on your specific condition and treatment plan. For example, some protocols involve treatments twice weekly for several weeks, followed by less frequent treatments[1].

Potential Side Effects

While methoxsalen with ECP is generally well-tolerated, it can have some side effects. These may include:

  • Nausea
  • Increased sensitivity to sunlight
  • Skin redness or itching
  • Fatigue

It’s important to discuss potential side effects with your healthcare provider before starting treatment[1].

Ongoing Research and Future Applications

Researchers continue to explore new potential uses for methoxsalen with ECP. Some areas of ongoing research include:

  • Using ECP with methoxsalen to prevent rejection in organ transplants[5].
  • Investigating its effectiveness in treating other autoimmune and inflammatory conditions[7].
  • Exploring its potential in managing side effects of cancer immunotherapy[8].

As research continues, we may discover more about how methoxsalen and ECP can be used to help patients with various conditions.

Aspect Details
Primary Uses Treatment of cutaneous T-cell lymphoma, graft-versus-host disease, immune-related conditions
Administration Method Typically used in combination with extracorporeal photopheresis (ECP)
Mechanism of Action Becomes activated by UVA light, modulates immune system responses
Conditions Studied Mycosis fungoides, acute graft-versus-host disease, Crohn’s disease, rheumatoid arthritis, immune-related colitis
Treatment Duration Varies by condition; often involves multiple sessions over weeks to months
Potential Benefits May improve skin lesions, reduce inflammation, modulate immune responses
Safety Profile Generally well-tolerated; potential side effects include nausea, skin sensitivity
Current Status Approved for some conditions; ongoing clinical trials for others

FAQ

  • What is methoxsalen and how does it work? Methoxsalen is a drug that becomes activated when exposed to ultraviolet A (UVA) light. It's often used in combination with a procedure called extracorporeal photopheresis (ECP), where blood cells are removed, treated with methoxsalen and UVA light, then returned to the patient. This process is thought to modulate the immune system.
  • What conditions is methoxsalen being studied for in clinical trials? Clinical trials are exploring methoxsalen for various conditions including cutaneous T-cell lymphoma, graft-versus-host disease, Crohn's disease, rheumatoid arthritis, and certain types of colitis. It's also being studied for its potential in treating complications from cancer immunotherapies.
  • How is methoxsalen typically administered in these trials? In most trials, methoxsalen is administered as part of extracorporeal photopheresis (ECP). This involves removing some of the patient's blood, treating it with methoxsalen and UVA light outside the body, then returning the treated blood to the patient. The frequency of treatments varies by study, but often involves multiple sessions over several weeks or months.
  • What are some potential side effects of methoxsalen treatment? While side effects can vary depending on the specific treatment protocol, some potential side effects of methoxsalen and ECP may include nausea, skin sensitivity to light, and temporary changes in blood cell counts. However, the treatment is generally considered to have a favorable safety profile compared to some other immunosuppressive therapies.
  • How effective has methoxsalen treatment been in clinical trials so far? The effectiveness of methoxsalen treatment varies depending on the condition being treated. Some trials have shown promising results, particularly in treating certain skin conditions and graft-versus-host disease. However, more research is needed to fully understand its efficacy across different diseases and to determine which patients are most likely to benefit from this treatment approach.

Ongoing Clinical Trials on Methoxsalen

  • Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study Comparing Methylprednisolone and Methoxsalen for Treating Grade II Acute Graft-Versus-Host Disease in Adult Stem Cell Transplant Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Methoxsalen for Treating Immune-Related Side Effects in Patients After Immunotherapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on the Effectiveness of Mesenchymal Stromal Cells in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

Glossary

  • Extracorporeal Photopheresis (ECP): A medical procedure where blood is temporarily removed from the body, treated with a drug and ultraviolet light, then returned to the patient. It's used to treat certain diseases by modulating the immune system.
  • Methoxsalen: Also known as 8-methoxypsoralen, it's a drug that becomes active when exposed to ultraviolet A (UVA) light. It's used in combination with ECP to treat various conditions.
  • Graft-versus-host Disease (GvHD): A complication that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient's body.
  • Cutaneous T-cell Lymphoma (CTCL): A rare type of cancer that begins in white blood cells called T-cells and primarily affects the skin.
  • Mycosis Fungoides: The most common form of cutaneous T-cell lymphoma, characterized by skin lesions that can progress to tumors and systemic disease.
  • Immune Checkpoint Inhibitor (ICI): A type of cancer immunotherapy that blocks certain proteins made by immune system cells, such as T cells, and some cancer cells.
  • Immune-related Colitis: Inflammation of the colon that can occur as a side effect of certain cancer immunotherapies.
  • PUVA: A treatment combining Psoralen (P) and long-wave Ultraviolet A (UVA) light, used for various skin conditions.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
  • Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.

References

  1. https://clinicaltrials.gov/study/NCT02524847
  2. https://clinicaltrials.gov/study/NCT01686594
  3. https://clinicaltrials.gov/study/NCT00002011
  4. https://clinicaltrials.gov/study/NCT00221039
  5. https://clinicaltrials.gov/study/NCT00054600
  6. https://clinicaltrials.gov/study/NCT00221026
  7. https://clinicaltrials.gov/study/NCT00221000
  8. https://clinicaltrials.gov/study/NCT06646016